Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Gynecology

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 160 articles:
HTML format
Text format



Single Articles


    August 2019
  1. RICE MS, Poole EM, Willett WC, Tworoger SS, et al
    Adult Dietary Fat Intake and Ovarian Cancer Risk.
    Int J Cancer. 2019 Aug 23. doi: 10.1002/ijc.32635.
    PubMed     Text format     Abstract available


  2. VINK FJ, Meijer CJLM, Clifford GM, Poljak M, et al
    FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study.
    Int J Cancer. 2019 Aug 7. doi: 10.1002/ijc.32614.
    PubMed     Text format     Abstract available


  3. RAY-COQUARD I, Cibula D, Mirza MR, Reuss A, et al
    Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer.
    Int J Cancer. 2019 Aug 5. doi: 10.1002/ijc.32606.
    PubMed     Text format     Abstract available


    July 2019
  4. TAWE L, MacDuffie E, Narasimhamurthy M, Wang Q, et al
    Human Papillomavirus (HPV) Genotypes in Women with Invasive Cervical Cancer with and without Human Immunodeficiency Virus (HIV) Infection in Botswana.
    Int J Cancer. 2019 Jul 20. doi: 10.1002/ijc.32581.
    PubMed     Text format     Abstract available


  5. RAAB M, Kobayashi NF, Becker S, Kurunci-Csacsko E, et al
    Boosting the apoptotic response of high grade serous ovarian cancers with CCNE1-amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
    Int J Cancer. 2019 Jul 8. doi: 10.1002/ijc.32559.
    PubMed     Text format     Abstract available


  6. ZHU Q, Zhang J, Chen Y, Hu Q, et al
    Whole-Exome Sequencing Of Ovarian Cancer Families Uncovers Putative Predisposition Genes.
    Int J Cancer. 2019 Jul 2. doi: 10.1002/ijc.32545.
    PubMed     Text format     Abstract available


    June 2019
  7. COLDMAN AJ, van Niekerk D, Krajden M, Smith LW, et al
    Disease Detection at the 48 Month Exit Round of the HPV FOCAL Cervical Cancer Screening Trial in Women Per-Protocol Eligible for Routine Screening.
    Int J Cancer. 2019 Jun 27. doi: 10.1002/ijc.32524.
    PubMed     Text format     Abstract available


  8. ROHNER E, Butikofer L, Schmidlin K, Sengayi M, et al
    Cervical cancer risk in women living with HIV across four continents: A multicohort study.
    Int J Cancer. 2019 Jun 19. doi: 10.1002/ijc.32260.
    PubMed     Text format     Abstract available


  9. GRUNDY A, Ho V, Abrahamowicz M, Parent ME, et al
    Lifetime recreational moderate-to-vigorous physical activity and ovarian cancer risk: a case-control study.
    Int J Cancer. 2019 Jun 14. doi: 10.1002/ijc.32513.
    PubMed     Text format     Abstract available


  10. COSTAS L, Frias-Gomez J, Guardiola M, Benavente Y, et al
    New perspectives on screening and early detection of endometrial cancer.
    Int J Cancer. 2019 Jun 14. doi: 10.1002/ijc.32514.
    PubMed     Text format     Abstract available


  11. DASHTI SG, Simpson JA, Karahalios A, Viallon V, et al
    Adiposity and estrogen receptor-positive, postmenopausal breast cancer risk: quantification of the mediating effects of fasting insulin and free estradiol.
    Int J Cancer. 2019 Jun 12. doi: 10.1002/ijc.32504.
    PubMed     Text format     Abstract available


  12. ZENG X, Baba T, Hamanishi J, Matsumura N, et al
    Phosphorylation of STAT1 serine 727 enhances platinum resistance in uterine serous carcinoma.
    Int J Cancer. 2019 Jun 10. doi: 10.1002/ijc.32501.
    PubMed     Text format     Abstract available


  13. TRABERT B, Troisi R, Grotmol T, Ekbom A, et al
    Associations of pregnancy-related factors and birth characteristics with risk of endometrial cancer: a Nordic population-based case-control study.
    Int J Cancer. 2019 Jun 7. doi: 10.1002/ijc.32494.
    PubMed     Text format     Abstract available


    May 2019
  14. MORI N, Sawada N, Iwasaki M, Yamaji T, et al
    Circulating sex hormone levels and colorectal cancer risk in Japanese postmenopausal women: The JPHC nested case-control study.
    Int J Cancer. 2019 May 27. doi: 10.1002/ijc.32431.
    PubMed     Text format     Abstract available


  15. WANG J, Elfstrom KM, Andrae B, Nordqvist Kleppe S, et al
    Cervical cancer case-control audit: Results from routine evaluation of a nationwide cervical screening programme.
    Int J Cancer. 2019 May 20. doi: 10.1002/ijc.32416.
    PubMed     Text format     Abstract available


  16. TIAN W, Bi R, Ren Y, He H, et al
    Screening for hereditary cancers in patients with endometrial cancer reveals a high frequency of germline mutations in cancer predisposition genes.
    Int J Cancer. 2019 May 4. doi: 10.1002/ijc.32389.
    PubMed     Text format     Abstract available


  17. KLEIBLOVA P, Stolarova L, Krizova K, Lhota F, et al
    Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer.
    Int J Cancer. 2019 May 3. doi: 10.1002/ijc.32385.
    PubMed     Text format     Abstract available


  18. BAO C, Yang R, Pedersen NL, Xu W, et al
    Overweight in midlife and risk of cancer in late life: A nationwide Swedish twin study.
    Int J Cancer. 2019;144:2128-2134.
    PubMed     Text format     Abstract available


    April 2019
  19. ASSI N, Rinaldi S, Viallon V, Dashti SG, et al
    Mediation analysis of the alcohol-postmenopausal breast cancer relationship by sex hormones in the EPIC Cohort.
    Int J Cancer. 2019 Apr 10. doi: 10.1002/ijc.32324.
    PubMed     Text format     Abstract available


  20. CABASAG CJ, Arnold M, Butler J, Inoue M, et al
    The influence of birth cohort and calendar period on global trends in ovarian cancer incidence.
    Int J Cancer. 2019 Apr 10. doi: 10.1002/ijc.32322.
    PubMed     Text format     Abstract available


  21. AMARO-FILHO SM, Gradissimo A, Usyk M, Moreira FCB, et al
    HPV73 a non-vaccine type causes cervical cancer.
    Int J Cancer. 2019 Apr 9. doi: 10.1002/ijc.32315.
    PubMed     Text format     Abstract available


    March 2019
  22. NURMI A, Muranen TA, Pelttari LM, Kiiski JI, et al
    Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.
    Int J Cancer. 2019 Mar 30. doi: 10.1002/ijc.32309.
    PubMed     Text format     Abstract available


  23. TIAN J, Geng Y, Lv D, Li P, et al
    Using plasma cell free DNA to monitor the chemo-radiotherapy course of cervical cancer.
    Int J Cancer. 2019 Mar 28. doi: 10.1002/ijc.32295.
    PubMed     Text format     Abstract available


  24. LI H, Zhang W, Niu C, Lin C, et al
    Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
    Int J Cancer. 2019 Mar 20. doi: 10.1002/ijc.32293.
    PubMed     Text format     Abstract available


  25. BALLABIO S, Craparotta I, Paracchini L, Mannarino L, et al
    Multisite analysis of high-grade serous epithelial ovarian cancers identifies genomic regions of focal and recurrent copy number variation in 3p26.2 and 8q24.3.
    Int J Cancer. 2019 Mar 20. doi: 10.1002/ijc.32288.
    PubMed     Text format     Abstract available


    February 2019

  26. Expression of Concern: "Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells" by Hua Yang, Lili He, Patricia Kruk, Santo V. Nicosia and Jin Q. Cheng.
    Int J Cancer. 2019 Feb 27. doi: 10.1002/ijc.32225.
    PubMed     Text format    


  27. HE Y, Gu Z, Zhu Q, Chen M, et al
    CA125 over-release behavior following a 75-gram oral glucose test as a predictive biomarker of multidrug resistance in patients with ovarian cancer.
    Int J Cancer. 2019 Feb 26. doi: 10.1002/ijc.32237.
    PubMed     Text format     Abstract available


  28. ARRIAGA ME, Vajdic CM, Canfell K, MacInnis RJ, et al
    The preventable burden of breast cancers for premenopausal and postmenopausal women in Australia: a pooled cohort study.
    Int J Cancer. 2019 Feb 25. doi: 10.1002/ijc.32231.
    PubMed     Text format     Abstract available


  29. VAN LEEUWEN RW, Ostrbenk A, Poljak M, van der Zee AGJ, et al
    DNA methylation markers as a triage test for identification of cervical lesions in a high risk human papillomavirus positive screening cohort.
    Int J Cancer. 2019;144:746-754.
    PubMed     Text format     Abstract available


    January 2019
  30. BHASKARAN SP, Chandratre K, Gupta H, Zhang L, et al
    Germline variation in BRCA1/2 is highly ethnic-specific: evidence from over 30,000 Chinese hereditary breast and ovarian cancer patients.
    Int J Cancer. 2019 Jan 31. doi: 10.1002/ijc.32176.
    PubMed     Text format     Abstract available


  31. LI F, Li H, Zhang L, Li W, et al
    X chromosome-linked long noncoding RNA lnc-XLEC1 regulates c-Myc-dependent cell growth by collaborating with MBP-1 in endometrial cancer.
    Int J Cancer. 2019 Jan 30. doi: 10.1002/ijc.32166.
    PubMed     Text format     Abstract available


  32. RIOS P, Bailey HD, Poulalhon C, Valteau-Couanet D, et al
    Parental smoking, maternal alcohol consumption during pregnancy and the risk of neuroblastoma in children. A pooled analysis of the ESCALE and ESTELLE French studies.
    Int J Cancer. 2019 Jan 29. doi: 10.1002/ijc.32161.
    PubMed     Text format     Abstract available


  33. KAWAKITA D, Lee YA, Gren LH, Buys SS, et al
    Fiber Intake and the Risk of Head and Neck Cancer in the prostate, lung, colorectal, and ovarian (PLCO) cohort.
    Int J Cancer. 2019 Jan 29. doi: 10.1002/ijc.32162.
    PubMed     Text format     Abstract available


  34. TRABERT B, Michels KA, Anderson GL, Brinton LA, et al
    Circulating androgens and postmenopausal ovarian cancer risk in the Women's Health Initiative Observational Study.
    Int J Cancer. 2019 Jan 26. doi: 10.1002/ijc.32157.
    PubMed     Text format     Abstract available


  35. CERVENKA I, Al Rahmoun M, Mahamat Saleh Y, Savoye I, et al
    Postmenopausal hormone use and cutaneous melanoma risk: A French prospective cohort study.
    Int J Cancer. 2019 Jan 22. doi: 10.1002/ijc.32150.
    PubMed     Text format     Abstract available


  36. BRANDAO RD, Mensaert K, Lopez-Perolio I, Tserpelis D, et al
    Targeted RNA-seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes.
    Int J Cancer. 2019 Jan 8. doi: 10.1002/ijc.32114.
    PubMed     Text format     Abstract available


  37. LEEMAN A, Del Pino M, Marimon L, Torne A, et al
    Reliable identification of women with CIN3+ using hrHPV genotyping and methylation markers in a cytology-screened referral population.
    Int J Cancer. 2019;144:160-168.
    PubMed     Text format     Abstract available


    December 2018
  38. VAN HELLEMOND IEG, Vriens IJH, Peer PGM, Swinkels ACP, et al
    Efficacy of Anastrozole after Tamoxifen in Early Breast Cancer Patients with Chemotherapy-Induced Ovarian Function Failure.
    Int J Cancer. 2018 Dec 26. doi: 10.1002/ijc.32093.
    PubMed     Text format     Abstract available


  39. FORTNER RT, Poole EM, Wentzensen NA, Trabert B, et al
    Ovarian cancer risk factors by tumor aggressiveness: an analysis from the Ovarian Cancer Cohort Consortium.
    Int J Cancer. 2018 Dec 18. doi: 10.1002/ijc.32075.
    PubMed     Text format     Abstract available


  40. HAMERS FF, Assogba FAG, Rogel A
    Implementation and organization of cancer screening in France.
    Int J Cancer. 2018;143:3281.
    PubMed     Text format    


  41. ANDREASSEN T, Hansen BT, Engesaeter B, Hashim D, et al
    Psychological Effect of Cervical Cancer Screening When Changing Primary Screening Method From Cytology to hrHPV testing.
    Int J Cancer. 2018 Dec 14. doi: 10.1002/ijc.32067.
    PubMed     Text format     Abstract available


  42. RADER JS, Tsaih SW, Fullin D, Murray MW, et al
    Genetic variations in human papillomavirus and cervical cancer outcomes.
    Int J Cancer. 2018 Dec 4. doi: 10.1002/ijc.32038.
    PubMed     Text format     Abstract available


  43. HALEC G, Scott ME, Farhat S, Darragh TM, et al
    Toll-like receptors: Important immune checkpoints in the regression of cervical intra-epithelial neoplasia 2.
    Int J Cancer. 2018;143:2884-2891.
    PubMed     Text format     Abstract available


    November 2018
  44. KIM S, Wang M, Tyrer JP, Jensen A, et al
    A Comprehensive Gene-Environment Interaction Analysis in Ovarian Cancer using Genome-wide Significant Common Variants.
    Int J Cancer. 2018 Nov 29. doi: 10.1002/ijc.32029.
    PubMed     Text format     Abstract available


  45. UTADA M, Chernyavskiy P, Lee WJ, Franceschi S, et al
    Increasing risk of uterine cervical cancer among young Japanese women: Comparison of incidence trends in Japan, South Korea and Japanese-Americans between 1985 and 2012.
    Int J Cancer. 2018 Nov 25. doi: 10.1002/ijc.32014.
    PubMed     Text format     Abstract available


  46. POLMAN NJ, Veldhuijzen NJ, Heideman DAM, Snijders PJF, et al
    Management of HPV-Positive Women in Cervical Screening Using Results from Two Consecutive Screening Rounds.
    Int J Cancer. 2018 Nov 22. doi: 10.1002/ijc.32004.
    PubMed     Text format     Abstract available


  47. SCHUBERT S, van Luttikhuizen JL, Auber B, Schmidt G, et al
    The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: high frequency of FANCM pathogenic variants.
    Int J Cancer. 2018 Nov 13. doi: 10.1002/ijc.31992.
    PubMed     Text format     Abstract available


  48. RATAJ O, Haedicke-Jarboui J, Stubenrauch F, Iftner T, et al
    Brd4 inhibition suppresses HPV16 E6 expression and enhances chemoresponse: A potential new target in cervical cancer therapy.
    Int J Cancer. 2018 Nov 13. doi: 10.1002/ijc.31986.
    PubMed     Text format     Abstract available


  49. COOK DA, Krajden M, Brentnall AR, Gondara L, et al
    Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial.
    Int J Cancer. 2018 Nov 9. doi: 10.1002/ijc.31976.
    PubMed     Text format     Abstract available


  50. ISIDEAN SD, Wang Y, Mayrand MH, Ratnam S, et al
    Assessing the Time Dependence of Prognostic Values of Cytology and Human Papillomavirus Testing in Cervical Cancer Screening.
    Int J Cancer. 2018 Nov 9. doi: 10.1002/ijc.31970.
    PubMed     Text format     Abstract available


  51. RAGLAN O, Kalliala I, Markozannes G, Cividini S, et al
    Risk Factors for Endometrial Cancer: An umbrella review of the literature.
    Int J Cancer. 2018 Nov 2. doi: 10.1002/ijc.31961.
    PubMed     Text format     Abstract available


  52. PIMENOFF VN, Tous S, Benavente Y, Alemany L, et al
    Distinct geographic clustering of oncogenic human papillomaviruses multiple infections in cervical cancers: results from a worldwide cross-sectional study.
    Int J Cancer. 2018 Nov 2. doi: 10.1002/ijc.31964.
    PubMed     Text format     Abstract available


    October 2018
  53. KAMINENI A, Tiro JA, Beaber EF, Silverberg MJ, et al
    Cervical Cancer Screening Research in the PROSPR I Consortium: Rationale, Methods, and Baseline Findings from a U.S. Cohort.
    Int J Cancer. 2018 Oct 24. doi: 10.1002/ijc.31940.
    PubMed     Text format     Abstract available


  54. MACKINTOSH ML, Derbyshire AE, McVey RJ, Bolton J, et al
    The impact of obesity and bariatric surgery on circulating and tissue biomarkers of endometrial cancer risk.
    Int J Cancer. 2018 Oct 5. doi: 10.1002/ijc.31913.
    PubMed     Text format     Abstract available


    September 2018
  55. ELANDS RJ, Offermans NS, Simons CC, Schouten LJ, et al
    Associations of adult-attained height and early life energy restriction with postmenopausal breast cancer risk according to estrogen and progesterone receptor status.
    Int J Cancer. 2018 Sep 25. doi: 10.1002/ijc.31890.
    PubMed     Text format     Abstract available


  56. SAND FL, Munk C, Frederiksen K, Junge J, et al
    Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV types.
    Int J Cancer. 2018 Sep 24. doi: 10.1002/ijc.31883.
    PubMed     Text format     Abstract available


  57. LIU Z, Zhang S, Hou F, Zhang C, et al
    Inhibition of Ca(2+) -activated chloride channel ANO1 suppresses ovarian cancer through inactivating PI3K/Akt signaling.
    Int J Cancer. 2018 Sep 22. doi: 10.1002/ijc.31887.
    PubMed     Text format     Abstract available


  58. TSANG SH, Peisch SF, Rowan B, Markt SC, et al
    Association between Trichomonas vaginalis and prostate cancer mortality.
    Int J Cancer. 2018 Sep 22. doi: 10.1002/ijc.31885.
    PubMed     Text format     Abstract available


  59. WANG Q, Song R, Zhao C, Liu H, et al
    HPV16 E6 promotes cervical cancer cell migration and invasion by downregulation of NHERF1.
    Int J Cancer. 2018 Sep 19. doi: 10.1002/ijc.31876.
    PubMed     Text format     Abstract available


  60. MONDAL S, Roy D, Sarkar Bhattacharya S, Jin L, et al
    Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers.
    Int J Cancer. 2018 Sep 18. doi: 10.1002/ijc.31868.
    PubMed     Text format     Abstract available


  61. KOMEMI O, Epstein Shochet G, Pomeranz M, Fishman A, et al
    Placenta-conditioned extracellular matrix (ECM) activates breast cancer cell survival mechanisms: A key for future distant metastases.
    Int J Cancer. 2018 Sep 8. doi: 10.1002/ijc.31861.
    PubMed     Text format     Abstract available


  62. SNOEK BC, Verlaat W, Babion I, Novianti PW, et al
    Genome-wide microRNA analysis of HPV-positive self-samples yields novel triage markers for early detection of cervical cancer.
    Int J Cancer. 2018 Sep 7. doi: 10.1002/ijc.31855.
    PubMed     Text format     Abstract available


  63. FALK RT, Manson JE, Barnabei VM, Anderson GL, et al
    Estrogen metabolism in menopausal hormone users in the Women's Health Initiative Observational Study: Does it differ between estrogen plus progestin and estrogen alone?
    Int J Cancer. 2018 Sep 5. doi: 10.1002/ijc.31851.
    PubMed     Text format     Abstract available


  64. LI J, Wen WX, Eklund M, Kvist A, et al
    Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort.
    Int J Cancer. 2018 Sep 2. doi: 10.1002/ijc.31841.
    PubMed     Text format     Abstract available


  65. BAUSSANO I, Lazzarato F, Ronco G, Franceschi S, et al
    Impacts of human papillomavirus vaccination for different populations: A modeling study.
    Int J Cancer. 2018;143:1086-1092.
    PubMed     Text format     Abstract available


    August 2018
  66. ZHANG C, Wang X, Anaya Y, Parodi L, et al
    Distinct Molecular Pathways in Ovarian Endometrioid Adenocarcinoma with Concurrent Endometriosis.
    Int J Cancer. 2018 Aug 28. doi: 10.1002/ijc.31768.
    PubMed     Text format     Abstract available


  67. OSTERMAN AL, Winer RL, Gottlieb GS, Sy MP, et al
    Female genital mutilation and non-invasive cervical abnormalities and invasive cervical cancer in Senegal, West Africa: A retrospective study.
    Int J Cancer. 2018 Aug 24. doi: 10.1002/ijc.31829.
    PubMed     Text format     Abstract available


  68. JOSHI S, Muwonge R, Kulkarni V, Deodhar K, et al
    Incidence of cervical intraepithelial neoplasia in women infected with human immunodeficiency virus (HIV) with no evidence of disease at baseline: results of a prospective cohort study with up to 6.4 years of follow-up from India.
    Int J Cancer. 2018 Aug 22. doi: 10.1002/ijc.31826.
    PubMed     Text format     Abstract available


  69. CAMPOS NG, Tsu V, Jeronimo J, Regan C, et al
    Health impact of delayed implementation of cervical cancer screening programs in India: A modelling analysis.
    Int J Cancer. 2018 Aug 21. doi: 10.1002/ijc.31823.
    PubMed     Text format     Abstract available


  70. JIN C, Liu Z, Li Y, Bu H, et al
    PCNA-associated factor P15(PAF) , targeted by FOXM1, predicts poor prognosis in high-grade serous ovarian cancer patients.
    Int J Cancer. 2018 Aug 21. doi: 10.1002/ijc.31800.
    PubMed     Text format     Abstract available


  71. BUCCHI L, Baldacchini F, Mancini S, Ravaioli A, et al
    Estimating the impact of an organised screening programme on cervical cancer incidence: a 26-year study from northern Italy.
    Int J Cancer. 2018 Aug 18. doi: 10.1002/ijc.31806.
    PubMed     Text format     Abstract available


  72. LU X, Li Y, Xia B, Bai Y, et al
    Selection of small plasma peptides for the auxiliary diagnosis and prognosis of epithelial ovarian cancer by using UPLC/MS-based non-targeted and targeted analyses.
    Int J Cancer. 2018 Aug 16. doi: 10.1002/ijc.31807.
    PubMed     Text format     Abstract available


  73. KIVES Z, Juhasz K, Csakvari T, Agoston I, et al
    Cancer screening policy in Hungary.
    Int J Cancer. 2018;143:1003-1004.
    PubMed     Text format    


  74. NEFF R, Rush CM, Smith B, Backes FJ, et al
    Functional characterization of recurrent FOXA2 mutations seen in endometrial cancers.
    Int J Cancer. 2018 Aug 9. doi: 10.1002/ijc.31784.
    PubMed     Text format     Abstract available


  75. HE W, Hou M, Zhang H, Zeng C, et al
    Clinical significance of circulating tumor cells in predicting disease progression and chemotherapy resistance in patients with gestational choriocarcinoma.
    Int J Cancer. 2018 Aug 2. doi: 10.1002/ijc.31742.
    PubMed     Text format     Abstract available


  76. CHUANG SC, Lin CH, Lu YS, Hsiung CA, et al
    Association of pregnancy and mortality in women diagnosed with breast cancer: A nationwide population based study in Taiwan.
    Int J Cancer. 2018 Aug 2. doi: 10.1002/ijc.31777.
    PubMed     Text format     Abstract available


  77. GOMIH A, Smith JS, North KE, Hudgens MG, et al
    DNA methylation of imprinted gene control regions in the regression of low-grade cervical lesions.
    Int J Cancer. 2018;143:552-560.
    PubMed     Text format     Abstract available


    July 2018
  78. CHEN HJ, Huang RL, Liew PL, Su PH, et al
    GATA3 as a master regulator and therapeutic target in ovarian high-grade serous carcinoma stem cells.
    Int J Cancer. 2018 Jul 14. doi: 10.1002/ijc.31750.
    PubMed     Text format     Abstract available


  79. AKINWUNMI B, Vitonis AF, Titus L, Terry KL, et al
    Statin Therapy and Association with Ovarian Cancer risk in the New England Case Control (NEC) Study.
    Int J Cancer. 2018 Jul 14. doi: 10.1002/ijc.31758.
    PubMed     Text format     Abstract available


  80. TESCH H, Stoetzer O, Decker T, Kurbacher CM, et al
    Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial
    Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31738.
    PubMed     Text format     Abstract available


  81. CLENDENEN TV, Dorgan J, Zeleniuch-Jacquotte A
    Reply to: Anti-Mullerian hormone and breast cancer risk- is the correlation possibly associated with the PCOS?
    Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31728.
    PubMed     Text format    


  82. BLUMENFELD Z
    Anti-Mullerian hormone and breast cancer risk- is the correlation possibly associated with the PCOS?
    Int J Cancer. 2018 Jul 10. doi: 10.1002/ijc.31732.
    PubMed     Text format    


  83. SAAVALAINEN L, Lassus H, But A, Tiitinen A, et al
    A nationwide cohort study on the risk of non-gynaecological cancers in women with surgically verified endometriosis.
    Int J Cancer. 2018 Jul 7. doi: 10.1002/ijc.31721.
    PubMed     Text format     Abstract available


  84. AUSTRIA T, Marion C, Yu V, Widschwendter M, et al
    Mechanism of cytokinesis failure in ovarian cystadenomas with defective brca1 and p53 pathways.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31659.
    PubMed     Text format     Abstract available


  85. CERVENKA I, Mahamat-Saleh Y, Savoye I, Dartois L, et al
    Oral contraceptive use and cutaneous melanoma risk: A french prospective cohort study.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31644.
    PubMed     Text format     Abstract available


  86. JASKULSKI S, Jung AY, Behrens S, Johnson T, et al
    Circulating enterolactone concentrations and prognosis of postmenopausal breast cancer: Assessment of mediation by inflammatory markers.
    Int J Cancer. 2018 Jul 4. doi: 10.1002/ijc.31647.
    PubMed     Text format     Abstract available


    June 2018
  87. GUSTAVSSON I, Aarnio R, Berggrund M, Hedlund-Lindberg J, et al
    Randomized study of HPV prevalence and detection of CIN2+ in vaginal self-sampling compared to cervical specimens collected by medical personnel.
    Int J Cancer. 2018 Jun 26. doi: 10.1002/ijc.31637.
    PubMed     Text format     Abstract available


  88. REZHAKE R, Hu SY, Zhao S, Xu XQ, et al
    Eight-type human papillomavirus E6/E7 oncoprotein detection as a novel and promising triage strategy for managing HPV-positive women.
    Int J Cancer. 2018 Jun 26. doi: 10.1002/ijc.31633.
    PubMed     Text format     Abstract available


  89. DYG SPERLING C, Verdoodt F, Kjaer Hansen M, Dehlendorff C, et al
    Statin use and mortality among endometrial cancer patients: a Danish nationwide cohort study.
    Int J Cancer. 2018 Jun 19. doi: 10.1002/ijc.31625.
    PubMed     Text format     Abstract available


  90. KO KP, Kim SJ, Huzarski T, Gronwald J, et al
    The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers.
    Int J Cancer. 2018;142:2263-2272.
    PubMed     Text format     Abstract available


    May 2018
  91. OLORUNFEMI G, Ndlovu N, Masukume G, Chikandiwa A, et al
    Temporal trends in the epidemiology of cervical cancer in South Africa (1994-2012).
    Int J Cancer. 2018 May 22. doi: 10.1002/ijc.31610.
    PubMed     Text format     Abstract available


  92. TROISI R, Gulbech Ording A, Grotmol T, Glimelius I, et al
    Pregnancy Complications and Subsequent Breast Cancer Risk in the Mother: A Nordic population-based case-control study.
    Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31600.
    PubMed     Text format     Abstract available


  93. BIZZARO F, Falcetta F, D'Agostini E, Decio A, et al
    Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab.
    Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31596.
    PubMed     Text format     Abstract available


  94. SKOLD C, Bjorge T, Ekbom A, Engeland A, et al
    Preterm delivery is associated with an increased risk of epithelial ovarian cancer among parous women.
    Int J Cancer. 2018 May 8. doi: 10.1002/ijc.31581.
    PubMed     Text format     Abstract available


  95. HUANG RL, Chen HJ, Chen LY, Chao TK, et al
    Epigenetic loss of heparan sulfate 3-O-sulfation sensitizes ovarian carcinoma to oncogenic signals and predicts prognosis.
    Int J Cancer. 2018 May 7. doi: 10.1002/ijc.31580.
    PubMed     Text format     Abstract available


    April 2018
  96. CHAN KK, Wong OG, Wong ES, Chan KK, et al
    Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31535.
    PubMed     Text format     Abstract available


  97. DE STROOPER LMA, Berkhof J, Steenbergen RDM, Lissenberg-Witte BI, et al
    Cervical cancer risk in HPV-positive women after a negative FAM19A4/mir124-2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow-up.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31539.
    PubMed     Text format     Abstract available


  98. CHAN KK, Wong OG, Wong ES, Chan KK, et al
    Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
    Int J Cancer. 2018 Apr 12. doi: 10.1002/ijc.31427.
    PubMed     Text format     Abstract available


  99. AGOSTINI A, Brunetti M, Davidson B, Trope CG, et al
    Identification of novel cyclin gene fusion transcripts in endometrioid ovarian carcinomas.
    Int J Cancer. 2018 Apr 6. doi: 10.1002/ijc.31418.
    PubMed     Text format     Abstract available


  100. CUBURU N, Khan S, Thompson CD, Kim R, et al
    Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8(+) T cell responses against HPV16 oncoproteins.
    Int J Cancer. 2018;142:1467-1479.
    PubMed     Text format     Abstract available


    March 2018
  101. ANNUNZIATA C, Pezzuto F, Greggi S, Ionna F, et al
    Distinct profiles of TERT promoter mutations and telomerase expression in head and neck cancer and cervical carcinoma.
    Int J Cancer. 2018 Mar 31. doi: 10.1002/ijc.31412.
    PubMed     Text format     Abstract available


  102. GUINTER MA, McLain AC, Merchant AT, Sandler DP, et al
    A dietary pattern based on estrogen metabolism is associated with breast cancer risk in a prospective cohort of postmenopausal women.
    Int J Cancer. 2018 Mar 25. doi: 10.1002/ijc.31387.
    PubMed     Text format     Abstract available


  103. PAPAEVANGELOU E, Almeida GS, Box C, deSouza NM, et al
    The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model.
    Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31392.
    PubMed     Text format     Abstract available


  104. KELLEN E, Benoy I, Vanden Broeck D, Martens P, et al
    A randomized, controlled trial of two strategies of offering the home-based HPV self-sampling test to non- participants in the Flemish cervical cancer screening program.
    Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31391.
    PubMed     Text format     Abstract available


  105. GUO W, Key TJ, Reeves GK
    Adiposity and breast cancer risk in postmenopausal women: Results from the UK Biobank prospective cohort.
    Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31394.
    PubMed     Text format     Abstract available


  106. VINTERMYR OK, Andersland MS, Bjorge T, Skar R, et al
    Human papillomavirus type specific risk of progression and remission during long term follow-up of equivocal and low grade HPV-positive cervical smears.
    Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31390.
    PubMed     Text format     Abstract available


  107. BROOKS JD, Sung JS, Pike MC, Orlow I, et al
    MRI background parenchymal enhancement, breast density and serum hormones in postmenopausal women.
    Int J Cancer. 2018 Mar 9. doi: 10.1002/ijc.31370.
    PubMed     Text format     Abstract available


  108. YU L, Jiang M, Qu P, Wu Z, et al
    Clinical Evaluation of Human Papillomavirus 16/18 Oncoprotein Test for Cervical Cancer Screening and HPV Positive Women Triage.
    Int J Cancer. 2018 Mar 9. doi: 10.1002/ijc.31368.
    PubMed     Text format     Abstract available


  109. WRIGHT LB, Schoemaker MJ, Jones ME, Ashworth A, et al
    Breast cancer risk in relation to history of preeclampsia and hyperemesis gravidarum: Prospective analysis in the Generations Study.
    Int J Cancer. 2018 Mar 8. doi: 10.1002/ijc.31364.
    PubMed     Text format     Abstract available


  110. LEHTINEN M, Soderlund-Strand A, Vanska S, Luostarinen T, et al
    Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I).
    Int J Cancer. 2018;142:949-958.
    PubMed     Text format     Abstract available


    February 2018
  111. KABAT GC, Kim MY, Stefanick M, Ho GYF, et al
    Metabolic obesity phenotypes and risk of colorectal cancer in postmenopausal women.
    Int J Cancer. 2018 Feb 27. doi: 10.1002/ijc.31345.
    PubMed     Text format     Abstract available


  112. KAAKS R, Fortner RT, Husing A, Barrdahl M, et al
    Tumor-associated auto-antibodies as early detection markers for ovarian cancer? A prospective evaluation.
    Int J Cancer. 2018 Feb 22. doi: 10.1002/ijc.31335.
    PubMed     Text format     Abstract available


  113. DEL MISTRO A, Adcock R, Carozzi F, Gillio-Tos A, et al
    HPV genotyping for the cross-sectional and longitudinal probability of developing CIN2.
    Int J Cancer. 2018 Feb 17. doi: 10.1002/ijc.31326.
    PubMed     Text format     Abstract available


  114. LIEW PL, Huang RL, Weng YC, Fang CL, et al
    Distinct methylation profile of mucinous ovarian carcinoma reveals susceptibility to proteasome inhibitors.
    Int J Cancer. 2018 Feb 16. doi: 10.1002/ijc.31324.
    PubMed     Text format     Abstract available


  115. RIETBERGEN MM, van Bokhoven AAJD, Lissenberg-Witte BI, Heideman DAM, et al
    Epidemiologic associations of HPV-positive oropharyngeal cancer and (pre)cancerous cervical lesions.
    Int J Cancer. 2018 Feb 14. doi: 10.1002/ijc.31315.
    PubMed     Text format     Abstract available


  116. LECAVALIER-BARSOUM M, Chaudary N, Han K, Koritzinsky M, et al
    Targeting the CXCL12/CXCR4 Pathway and Myeloid Cells to Improve Radiation Treatment of Locally Advanced Cervical Cancer.
    Int J Cancer. 2018 Feb 8. doi: 10.1002/ijc.31297.
    PubMed     Text format     Abstract available


  117. FALCONER H, Yin L, Altman D
    Association between tubal ligation and endometrial cancer risk: A Swedish population-based cohort study.
    Int J Cancer. 2018 Feb 1. doi: 10.1002/ijc.31287.
    PubMed     Text format     Abstract available


    January 2018
  118. YANG X, Wang N, Chen J
    Subsequent primary malignancies after endometrial cancer diagnosed in American cancer registries.
    Int J Cancer. 2018 Jan 31. doi: 10.1002/ijc.31284.
    PubMed     Text format    


  119. ZHENG J, Merchant AT, Wirth MD, Zhang J, et al
    Inflammatory potential of diet and risk of pancreatic cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
    Int J Cancer. 2018 Jan 22. doi: 10.1002/ijc.31271.
    PubMed     Text format     Abstract available


  120. LOKKEGAARD ECL, Morch LS
    Tibolone and risk of gynecological hormone sensitive cancer.
    Int J Cancer. 2018 Jan 19. doi: 10.1002/ijc.31267.
    PubMed     Text format     Abstract available


  121. DE KOK IMCM, Korfage IJ, van den Hout WB, Helmerhorst TJM, et al
    Quality of life assumptions determine which cervical cancer screening strategies are cost-effective.
    Int J Cancer. 2018 Jan 19. doi: 10.1002/ijc.31265.
    PubMed     Text format     Abstract available


  122. BUSUND M, Bugge NS, Braaten T, Waaseth M, et al
    Progestin-Only and Combined Oral Contraceptives and Receptor-Defined Premenopausal Breast Cancer Risk: The Norwegian Women and Cancer Study.
    Int J Cancer. 2018 Jan 19. doi: 10.1002/ijc.31266.
    PubMed     Text format     Abstract available


  123. CUSCHIERI K, Ronco G, Lorincz A, Smith L, et al
    Eurogin Roadmap 2017: Triage strategies for the management of HPV-positive women in cervical screening programmes.
    Int J Cancer. 2018 Jan 17. doi: 10.1002/ijc.31261.
    PubMed     Text format     Abstract available


  124. BASU P, Ponti A, Anttila A, Ronco G, et al
    Status of implementation and organization of cancer screening in The European Union Member States-Summary results from the second European screening report.
    Int J Cancer. 2018;142:44-56.
    PubMed     Text format     Abstract available


    December 2017
  125. LUOSTARINEN T, Apter D, Dillner J, Eriksson T, et al
    Vaccination protects against invasive HPV-associated cancers.
    Int J Cancer. 2017 Dec 26. doi: 10.1002/ijc.31231.
    PubMed     Text format    


  126. GULTEKIN M, Zayifoglu Karaca M, Kucukyildiz I, Dundar S, et al
    Initial results of population based cervical cancer screening program using hpv testing in one million turkish women.
    Int J Cancer. 2017 Dec 13. doi: 10.1002/ijc.31212.
    PubMed     Text format     Abstract available


  127. KHAIRALLAH AS, Genestie C, Auguste A, Leary A, et al
    Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications.
    Int J Cancer. 2017 Dec 8. doi: 10.1002/ijc.31200.
    PubMed     Text format    


  128. SAND FL, Frederiksen K, Munk C, Jensen SM, et al
    Long-Term Risk of Cervical Cancer Following Conization of Cervical Intraepithelial Neoplasia Grade 3 - A Danish Nationwide Cohort Study.
    Int J Cancer. 2017 Dec 8. doi: 10.1002/ijc.31202.
    PubMed     Text format     Abstract available


  129. KANG YJ, Smith M, Barlow E, Coffey K, et al
    Vulvar cancer in high-income countries: Increasing burden of disease.
    Int J Cancer. 2017;141:2174-2186.
    PubMed     Text format     Abstract available


  130. REIMER D, Boesch M, Wolf D, Marth C, et al
    Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically relevant in predicting prognosis and platinum-response.
    Int J Cancer. 2017 Dec 1. doi: 10.1002/ijc.31186.
    PubMed     Text format     Abstract available


    November 2017
  131. JOHANSSON ALV, Andersson TM, Hsieh CC, Jirstrom K, et al
    Tumor characteristics and prognosis in women with pregnancy-associated breast cancer.
    Int J Cancer. 2017 Nov 23. doi: 10.1002/ijc.31174.
    PubMed     Text format     Abstract available


  132. FORTNER RT, Schock H, Le Cornet C, Husing A, et al
    Ovarian Cancer Early Detection by Circulating CA125 in the context of Anti-CA125 Autoantibody Levels: Results from the EPIC cohort.
    Int J Cancer. 2017 Nov 21. doi: 10.1002/ijc.31164.
    PubMed     Text format     Abstract available


  133. KIM J, Field A, Schultz KAP, Hill DA, et al
    The prevalence of DICER1 pathogenic variation in population databases.
    Int J Cancer. 2017;141:2030-2036.
    PubMed     Text format     Abstract available


  134. REGER MK, Zollinger TW, Liu Z, Jones JF, et al
    Dietary intake of isoflavones and coumestrol and the risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Int J Cancer. 2017 Nov 8. doi: 10.1002/ijc.31095.
    PubMed     Text format     Abstract available


  135. RASMUSSEN CL, Sand FL, Hoffmann Frederiksen M, Andersen KK, et al
    Does HPV status influence survival after vulvar cancer?
    Int J Cancer. 2017 Nov 1. doi: 10.1002/ijc.31139.
    PubMed     Text format     Abstract available


    October 2017
  136. CUPPENS T, Moisse M, Depreeuw J, Annibali D, et al
    Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways.
    Int J Cancer. 2017 Oct 24. doi: 10.1002/ijc.31129.
    PubMed     Text format     Abstract available


  137. FELIX AS, Brasky TM, Cohn DE, Mutch DG, et al
    Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study.
    Int J Cancer. 2017 Oct 24. doi: 10.1002/ijc.31127.
    PubMed     Text format     Abstract available


  138. MATSUZAKI S, Serada S, Hiramatsu K, Nojima S, et al
    Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer.
    Int J Cancer. 2017 Oct 21. doi: 10.1002/ijc.31124.
    PubMed     Text format     Abstract available


  139. LANDY R, Windridge P, Gillman MS, Sasieni PD, et al
    What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study.
    Int J Cancer. 2017 Oct 11. doi: 10.1002/ijc.31094.
    PubMed     Text format     Abstract available


  140. MATSUO K, Shimada M, Yamaguchi S, Kanao H, et al
    Identifying a candidate population for ovarian conservation in young women with clinical stage IB-IIB cervical cancer.
    Int J Cancer. 2017 Oct 4. doi: 10.1002/ijc.31084.
    PubMed     Text format     Abstract available


  141. PAN R, Zhu M, Yu C, Lv J, et al
    Cancer incidence and mortality: A cohort study in China, 2008-2013.
    Int J Cancer. 2017;141:1315-1323.
    PubMed     Text format     Abstract available


    September 2017
  142. VIDART D'EGURBIDE BAGAZGOITIA , Bailey HD, Orsi L, Lacour B, et al
    Maternal residential pesticide use during pregnancy and risk of malignant childhood brain tumors: A pooled analysis of the ESCALE and ESTELLE studies (SFCE).
    Int J Cancer. 2017 Sep 26. doi: 10.1002/ijc.31073.
    PubMed     Text format     Abstract available


  143. GAITSKELL K, Green J, Pirie K, Barnes I, et al
    Histological subtypes of ovarian cancer associated with parity and breastfeeding in the prospective Million Women Study.
    Int J Cancer. 2017 Sep 20. doi: 10.1002/ijc.31063.
    PubMed     Text format     Abstract available


  144. RICE MS, Rist PM, Winter AC, Kurth T, et al
    Migraine and invasive epithelial ovarian cancer risk in the Nurses' Health Study II and the Women's Health Study.
    Int J Cancer. 2017 Sep 20. doi: 10.1002/ijc.31062.
    PubMed     Text format     Abstract available


  145. JUNG S, Allen N, Arslan AA, Baglietto L, et al
    Anti-Mullerian Hormone and risk of ovarian cancer in nine cohorts.
    Int J Cancer. 2017 Sep 18. doi: 10.1002/ijc.31058.
    PubMed     Text format     Abstract available


  146. QUIST AJL, Inoue-Choi M, Weyer PJ, Anderson KE, et al
    Ingested nitrate and nitrite, disinfection by-products, and pancreatic cancer risk in postmenopausal women.
    Int J Cancer. 2017 Sep 16. doi: 10.1002/ijc.31055.
    PubMed     Text format     Abstract available


  147. FABER MT, Sand FL, Albieri V, Norrild B, et al
    Prevalence and type distribution of human papillomavirus in squamous cell carcinoma and intraepithelial neoplasia of the vulva.
    Int J Cancer. 2017;141:1161-1169.
    PubMed     Text format     Abstract available


  148. ZHANG Q, Dong L, Hu S, Feng R, et al
    Risk stratification and long-term risk prediction of E6 oncoprotein in a prospective screening cohort in China.
    Int J Cancer. 2017;141:1110-1119.
    PubMed     Text format     Abstract available


    August 2017
  149. RAKISLOVA N, Clavero O, Alemany L, Saco A, et al
    "Histological characteristics of HPV-associated and -independent squamous cell carcinomas of the vulva: A study of 1594 cases".
    Int J Cancer. 2017 Aug 17. doi: 10.1002/ijc.31006.
    PubMed     Text format     Abstract available


  150. CLARKE MA, Luhn P, Gage JC, Bodelon C, et al
    Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancer.
    Int J Cancer. 2017;141:701-710.
    PubMed     Text format     Abstract available


  151. CHASIMPHA SJD, Parkin DM, Masamba L, Dzamalala CP, et al
    Three-year cancer incidence in Blantyre, Malawi (2008-2010).
    Int J Cancer. 2017;141:694-700.
    PubMed     Text format     Abstract available


    July 2017
  152. KHAN S, Oosterhuis K, Wunderlich K, Bunnik EM, et al
    Development of a replication-deficient adenoviral vector-based vaccine candidate for the interception of HPV16- and HPV18-induced infections and disease.
    Int J Cancer. 2017;141:393-404.
    PubMed     Text format     Abstract available


  153. GU F, Zhang H, Hyland PL, Berndt S, et al
    Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia.
    Int J Cancer. 2017 Jul 12. doi: 10.1002/ijc.30883.
    PubMed     Text format     Abstract available


  154. VELDHUIJZEN NJ, Polman NJ, Snijders PJF, Meijer CJLM, et al
    Stratifying HPV-positive women for CIN3+ risk after one and two rounds of HPV-based screening.
    Int J Cancer. 2017 Jul 3. doi: 10.1002/ijc.30865.
    PubMed     Text format     Abstract available


    June 2017
  155. MATSUMOTO K, Yaegashi N, Iwata T, Yamamoto K, et al
    Early impact of the Japanese immunization program implemented before the HPV vaccination crisis.
    Int J Cancer. 2017 Jun 28. doi: 10.1002/ijc.30855.
    PubMed     Text format    


    May 2017
  156. AGORASTOS T, Chatzistamatiou K, Moysiadis T, Kaufmann AM, et al
    Human papillomavirus E7 protein detection as a method of triage to colposcopy of HPV positive women, in comparison to genotyping and cytology. Final results of the PIPAVIR study.
    Int J Cancer. 2017 May 3. doi: 10.1002/ijc.30761.
    PubMed     Text format    


  157. SHEN C, Liu Y, Shi S, Zhang R, et al
    Long-distance interaction of the integrated HPV fragment with MYC gene and 8q24.22 region up-regulating the allele-specific MYC expression in HeLa cells.
    Int J Cancer. 2017 May 3. doi: 10.1002/ijc.30763.
    PubMed     Text format     Abstract available


    April 2017
  158. DE MARTEL C, Plummer M, Vignat J, Franceschi S, et al
    Worldwide burden of cancer attributable to HPV by site, country and HPV type.
    Int J Cancer. 2017 Apr 1. doi: 10.1002/ijc.30716.
    PubMed     Text format     Abstract available


    January 2017
  159. MANCINI S, Ravaioli A, Giuliani O, Vattiato R, et al
    Incidence and survival trends of cervical adenocarcinoma in Italy: Cytology screening has become more effective in downstaging the disease but not in detecting its precursors.
    Int J Cancer. 2017;140:247-248.
    PubMed     Text format    


    December 2016
  160. BOGANI G, Chiappa V, Martinelli F, Raspagliesi F, et al
    Type-Specific HPV Infection Correlates with Risk of Recurrence of Vulvar Intraepithelial Neoplasia Usual Type.
    Int J Cancer. 2016 Dec 22. doi: 10.1002/ijc.30585.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: